Clene

Clene Stock-Based Compensation

The Stock-Based Compensation (SBC) of Clene (CLNN) as of Nov 16, 2026 is 6.38 M USD. In the previous year, Stock-Based Compensation (SBC) was 7.95 M USD — a change of -19.75% (lower).

Stock-Based Compensation

6.38 MUSD

YoY

-19.75%

Last updated:

Stock-Based Compensation (SBC) of Clene is 2025 6.38 M USD. Stock-Based Compensation (SBC) of Clene was 2024 7.95 M USD. It decreases by -19.75% lower compared to the previous year.

The Clene Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2018
269,000.00 USD
Jan 1, 2019
399,000.00 USD
Jan 1, 2020
761,000.00 USD
Jan 1, 2021
12.38 M USD
Jan 1, 2022
8.51 M USD
Jan 1, 2023
9.12 M USD
Jan 1, 2024
7.95 M USD
Jan 1, 2025
6.38 M USD
The Clene Stock-Based Compensation history
YEARStock-Based CompensationYoY
6.38 MUSD-19.75%
7.95 MUSD-12.77%
9.12 MUSD+7.10%
8.51 MUSD-31.26%
12.38 MUSD+1,527.33%
761,000.00USD+90.73%
399,000.00USD+48.33%
269,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clene Stock analysis

What does Clene do? Clene Inc develops therapeutic products for neurodegenerative diseases, focusing on targeting energetic failure as a root cause. Its primary product CNM-Au8 is an oral suspension of gold nanocrystals designed to restore neuronal health by enhancing energy production and utilization. The company also develops CNM-ZnAg, a spectrum antiviral and antibacterial agent containing zinc and silver ions for infectious disease treatment and immune support, and CNM-AgZn17, a gel polymer suspension of zinc and silver for wound healing and infectious disease management. These products are intended for clinical development and eventual commercialization in the pharmaceutical market. Clene's target customers are patients suffering from neurodegenerative diseases and infectious conditions requiring antiviral, antibacterial, or wound healing solutions. The company's products aim to address unmet medical needs in these therapeutic areas by leveraging innovative nanocrystal and ion-based technologies. The firm operates within the biopharmaceutical sector, developing treatments that focus on cellular energy processes to provide neuroprotection and remyelination. The company generates revenue through the development and potential future commercialization of its drug candidates. CNM-Au8 targets neurodegenerative diseases by addressing energetic failure, while CNM-ZnAg and CNM-AgZn17 focus on infectious disease treatment and wound healing applications. These products are in clinical development stages, with the company seeking to advance them toward regulatory approval and market entry. Clene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clene stock

Stock-Based Compensation (SBC) of Clene is 6.38 M USD in 2025.

Stock-Based Compensation (SBC) of Clene changed from 7.95 M USD to 6.38 M USD, representing a -19.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Clene since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Clene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Clene

All Key Metrics — Clene